Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;12(7):3764-3773.
doi: 10.21037/jtd-20-1882.

First-line treatment selection with organoids of an EGFR m + TP53 m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

Ziqi Jia  1   2 , Yanyu Wang  1 , Lei Cao  1 , Yadong Wang  1 , Yang Song  1 , Xiaoying Yang  1   2 , Zhongxing Bing  1 , Zhili Cao  1 , Peng Liu  3 , Shuyang Zhang  3   4 , Zexin Chen  5 , Min Huang  5 , Yan Yu  5 , Han Han-Zhang  6 , Jinlei Song  6 , Daniel C Christoph  7 , Antonio Passaro  8 , Cesare Gridelli  9 , Tomoyuki Hishida  10 , Naixin Liang  1 , Shanqing Li  1
Affiliations
Review

First-line treatment selection with organoids of an EGFR m + TP53 m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

Ziqi Jia et al. J Thorac Dis. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-1882). ZJ reports grants from Beijing Students’ platform for innovation and entrepreneurship training program, during the conduct of the study. ZC reports personal fees from Accurate International Biotechnology Co. Ltd, during the conduct of the study. MH reports personal fees from Accurate International Biotechnology Co. Ltd., during the conduct of the study. YY reports personal fees from Accurate International Biotechnology Co. Ltd, during the conduct of the study. HHZ reports personal fees from Burning Rock Biotechnology Co. Ltd., during the conduct of the study. JS reports personal fees from Burning Rock Biotechnology Co. Ltd., during the conduct of the study. DCC reports personal fees, non-financial support and other from AstraZeneca, personal fees, non-financial support and other from Bayer, personal fees, non-financial support and other from Boehringer-Ingelheim, personal fees, non-financial support and other from Bristol-Myers Squibb, personal fees, non-financial support and other from Chugai, personal fees, non-financial support and other from Merck, Sharp & Dohme, personal fees, non-financial support and other from Novartis, personal fees, non-financial support and other from Pfizer, personal fees, non-financial support and other from Roche, personal fees, non-financial support and other from Takeda, outside the submitted work. AP reports personal fees from Roche, personal fees from BMS, personal fees from MSD, personal fees from Lilly, personal fees from Dako, personal fees from Astra Zeneca, outside the submitted work, and he serves as an unpaid editorial board member of Journal of Thoracic Disease from Aug 2019 to Jul 2021. CG reports personal fees from Astra Zeneca, grants and personal fees from MSD, personal fees from BMS, personal fees from Roche, personal fees from Menarini, personal fees from Novartis, outside the submitted work. NL reports grants from Beijing Natural Science Foundation, grants from Ministry of Science and Technology of the People’s Republic of China (MOST), grants from Chinese Academy of Medical Sciences Young Medical Talent Award Fund, grants from Beijing Students’ platform for innovation and entrepreneurship training program, grants from National Key Research and Development Program of China Grant, during the conduct of the study. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
18FDG-PET/CT scan showing a 1-cm nodule in the right supraclavicular fossa with increased avidity of SUVmax =4.2. 18FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography; SUVmax, maximum standard uptake value.
Figure 2
Figure 2
Pathological diagnosis of right supraclavicular lymph nodes as lymph node metastatic adenocarcinoma. HE staining, original magnification ×40.
Figure 3
Figure 3
Drug responses of patient-derived lymph node metastatic adenocarcinoma organoids. (A) Organoid culture of lymph node metastatic adenocarcinoma; (B) dose-response curves of patient-derived lymph node metastatic adenocarcinoma organoids treated with EGFR-TKI afatinib, osimertinib, erlotinib HCl, gefitinib, and icotinib. Cell viability was measured by an ATP-based assay after 4 days of drug incubation. TKI, tyrosine kinase inhibitor.
Figure 4
Figure 4
Effect of osimertinib in this patient with multiple mediastinal lymph node metastasis. Computed tomography scan of the chest before (A) and after (B) treatment with osimertinib. Shrinkage of multiple mediastinal lymph nodes (arrows) was observed.
See this image and copyright information in PMC

Comment in

References

    1. Deslypere G, Gullentops D, Wauters E, et al. Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? Ther Adv Med Oncol 2018;10:1758835918772810. 10.1177/1758835918772810 - DOI - PMC - PubMed
    1. Choi JI. Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes. Transl Lung Cancer Res 2019;8:32-47. 10.21037/tlcr.2018.06.11 - DOI - PMC - PubMed
    1. Sawabata N, Miyaoka E, Asamura H, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol 2011;6:1229-35. 10.1097/JTO.0b013e318219aae2 - DOI - PubMed
    1. Mitsudomi T, Suda K, Yatabe Y. Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol 2013;10:235. 10.1038/nrclinonc.2013.22 - DOI - PubMed
    1. Milano MT, Kong FM, Movsas B. Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy. Transl Lung Cancer Res 2019;8:78-87. 10.21037/tlcr.2018.08.15 - DOI - PMC - PubMed